Completion of Delayed Human Papillomavirus (HPV) Vaccination Series

Series Continuation After Long Interruption

The Advisory Committee on Immunization Practices (ACIP) states that the HPV vaccine series does not need to be restarted, regardless of how long the interruption has lasted; previous doses remain valid even after a 10‑year gap. 1
If the series is interrupted after the first dose, the next dose should be given as soon as possible without waiting for a specific interval. 1
The ACIP emphasizes that no maximum interval exists that would render earlier doses invalid, so a prolonged delay does not diminish the benefit of completing the series. 1

The American Academy of Pediatrics (AAP) recommends a 2‑dose schedule for individuals who receive the first dose before their 15th birthday; only one additional dose is needed to complete the series. 6
This 2‑dose schedule applies regardless of the timing of the subsequent dose(s); the interval between doses can be extended without affecting efficacy. 6

For persons who receive the first dose at age 15 or later, the AAP advises completing the standard 3‑dose schedule, requiring two additional doses. 6
The recommended timing for the 3‑dose series is dose 1 at month 0, dose 2 at 1–2 months, and dose 3 at ≥12 weeks after dose 2 (the preferred interval is 6 months). 1

The ACIP recommends routine catch‑up vaccination through age 26 for anyone who has not completed the series. 8
For adults aged 27–45, the ACIP advises shared clinical decision‑making based on individual risk assessment, acknowledging that vaccination may still be beneficial. 8
When the individual is ≤26 years old, completion of the series is strongly recommended without additional conditions. 8

The next dose should be administered immediately, without waiting for a specific interval from the long delay. 1
The 9‑valent HPV vaccine (9vHPV) is the only HPV vaccine currently available in the United States (as of 2017) and provides the broadest protection against oncogenic HPV types. 6
The HPV vaccine may be given concurrently with other indicated vaccines during the same visit. 1

The ACIP notes that vaccination remains substantially beneficial even for individuals who have been sexually active during the delay, because most have not yet been exposed to all vaccine‑covered HPV types. 1
Ongoing sexual activity maintains the risk of new HPV infection; therefore, catch‑up vaccination offers protection at any point in the sexually active lifespan. 1
No prior HPV testing or Pap smear is required before completing the series; vaccination proceeds regardless of previous exposure or cytology results. 1

Do not restart the series from dose 1; doing so discards the immunity already established by the initial dose. 1
Do not assume that three doses are needed without confirming the age at first vaccination; those who started before age 15 require only two total doses. 6
Do not delay series completion while awaiting HPV or cervical screening results; these are not prerequisites for vaccination. 1
Do not withhold vaccination based on presumed prior HPV exposure; even partial protection confers significant public‑health benefit. 1

HPV vaccination prevents an estimated 70–90 % of HPV‑related cancers, including cervical, oropharyngeal, anal, vaginal, vulvar, and penile malignancies. [6][8]